Literature DB >> 24850580

The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis.

J Van Schependom1, M B D'hooghe, K Cleynhens, M D'hooge, M C Haelewyck, J De Keyser, G Nagels.   

Abstract

BACKGROUND AND
PURPOSE: Cognitive impairment (CI) is found in about half of the multiple sclerosis (MS) population and is an important contributor to employment status and social functioning. CI is encountered in all disease stages and correlates only moderately with disease duration or Expanded Disability Status Scale scores. Most present neuropsychological test batteries are time-demanding and expensive. The Symbol Digit Modalities Test (SDMT) has been suggested as a screening tool for CI in MS. In this paper, we aim to assess the performance of the SDMT in predicting the outcome of an extensive battery.
METHODS: Neuropsychological test results from 359 patients were assessed in a multidisciplinary MS center (National MS Center Melsbroek, Belgium). Using receiver operating characteristic curves, the performance of the SDMT in predicting the general cognitive outcome of the extensive Neuropsychological Screening Battery for MS (NSBMS) could be assessed. The performance of the SDMT was assessed for different levels of CI and compared with other cognitive tests. Finally, useful covariates were included in a logistic regression model.
RESULTS: At a specificity of 0.60 a high sensitivity (0.91) was obtained indicating the potential of the SDMT as a sentinel test for CI in MS. The SDMT outperformed the individual tests included in the NSBMS, used as benchmark. As the logistic regression model did not result in a relevant improvement, it is concluded that most clinical variables influence both the SDMT and the NSBMS in a similar way. Excluding patients with possible practice effects, an optimal cutoff of 40 was found for the SDMT.
CONCLUSION: As the SDMT is an easy, low-cost and fast test, this result may help to detect CI in everyday clinical practice.
© 2014 The Author(s) European Journal of Neurology © 2014 EAN.

Entities:  

Keywords:  assessment of cognitive disorders; cognitive impairment; multiple sclerosis; sentinel test

Mesh:

Year:  2014        PMID: 24850580     DOI: 10.1111/ene.12463

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  42 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

2.  Altered hippocampal GABA and glutamate levels and uncoupling from functional connectivity in multiple sclerosis.

Authors:  Fei Gao; Xuntao Yin; Richard A E Edden; Alan C Evans; Junhai Xu; Guanmei Cao; Honghao Li; Muwei Li; Bin Zhao; Jian Wang; Guangbin Wang
Journal:  Hippocampus       Date:  2018-11       Impact factor: 3.899

3.  Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.

Authors:  Eldar Eftekhari; Seyed-Parsa Hojjat; Rita Vitorino; Timothy J Carroll; Charles Grady Cantrell; Liesly Lee; Matthew W Taylor; Sarah A Morrow; Haddas Benhabib; Richard I Aviv; Andrea Kassner
Journal:  Neuroradiology       Date:  2017-06-16       Impact factor: 2.804

Review 4.  Social Cognition in Multiple Sclerosis: a Meta-Analysis.

Authors:  Emre Bora; Serkan Özakbaş; Dennis Velakoulis; Mark Walterfang
Journal:  Neuropsychol Rev       Date:  2016-06-20       Impact factor: 7.444

5.  Screening Instruments for the Early Detection of Cognitive Impairment in Patients with Multiple Sclerosis.

Authors:  Sonya Kim; Vance Zemon; Joseph F Rath; MaryAnn Picone; Elizabeth S Gromisch; Heather Glubo; Lucia Smith-Wexler; Frederick W Foley
Journal:  Int J MS Care       Date:  2017 Jan-Feb

6.  The attentional cost of movement in multiple sclerosis.

Authors:  Douglas A Wajda; Tyler A Wood; Jacob J Sosnoff
Journal:  J Neural Transm (Vienna)       Date:  2019-03-25       Impact factor: 3.575

7.  Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members.

Authors:  Zongqi Xia; Sonya U Steele; Anshika Bakshi; Sarah R Clarkson; Charles C White; Matthew K Schindler; Govind Nair; Blake E Dewey; Lauren R Price; Joan Ohayon; Lori B Chibnik; Irene C M Cortese; Philip L De Jager; Daniel S Reich
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

8.  Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.

Authors:  Marcello Moccia; Roberta Lanzillo; Teresa Costabile; Cinzia Russo; Antonio Carotenuto; Gabriella Sasso; Emanuela Postiglione; Carla De Luca Picione; Michele Vastola; Giorgia Teresa Maniscalco; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

9.  The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis.

Authors:  Pinar Yigit; Ayla Acikgoz; Zaur Mehdiyev; Ayfer Dayi; Serkan Ozakbas
Journal:  Ir J Med Sci       Date:  2020-10-01       Impact factor: 1.568

10.  Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.

Authors:  Elizabeth A Mills; Joel A Begay; Caitlyn Fisher; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.